Abstract
AbstractAn attenuated SARS-CoV-2 virus with modified viral transcriptional regulatory sequences and deletion of open-reading frames 3, 6, 7 and 8 (∆3678) was previously reported to protect hamsters from SARS-CoV-2 infection and transmission. Here we report that a single-dose intranasal vaccination of ∆3678 protects K18-hACE2 mice from wild-type or variant SARS-CoV-2 challenge. Compared with wild-type virus infection, the ∆3678 vaccination induces equivalent or higher levels of lung and systemic T cell, B cell, IgA, and IgG responses. The results suggest ∆3678 as an attractive mucosal vaccine candidate to boost pulmonary immunity against SARS-CoV-2.
Funder
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
U.S. Department of Health & Human Services | National Institutes of Health
Sealy & Smith Foundation and the Kleberg Foundation
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Infectious Diseases,Pharmacology,Immunology
Reference21 articles.
1. Parums, V. Editorial: revised World Health Organization (WHO) Terminology for variants of concern and variants of interest of SARS-CoV-2. Med. Sci. Monit. 27, e933622 (2021).
2. Tang, J. et al. Respiratory mucosal immunity against SARS-CoV-2 following mRNA vaccination. Sci. Immunol. eadd4853 https://doi.org/10.1126/sciimmunol.add4853 (2022).
3. Lund, F. E. & Randall, T. D. Scent of a vaccine. Science 373, 397–399 (2021).
4. Teijaro, J. R. & Farber, D. L. COVID-19 vaccines: modes of immune activation and future challenges. Nat. Rev. Immunol. 21, 195–197 (2021).
5. Park, J. H. & Lee, H. K. Delivery Routes for COVID-19 Vaccines. Vaccines (Basel) 9 https://doi.org/10.3390/vaccines9050524 (2021).